Related Experiment Video
Updated: Dec 6, 2025
05:45
Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay
Published on: April 5, 2019
23.9K
A Robust Blood-based Signature of Cerebrospinal Fluid Aβ42 Status.
Summary
Early Alzheimer's detection is crucial. This study identifies blood biomarkers, including APOE4, EOT3, APOC1, CGA, and Aβ42, to predict cerebrospinal fluid amyloid levels non-invasively, aiding early diagnosis.
Area of Science:
- Neuroscience
- Biomarker Discovery
Background:
- Early detection of Alzheimer's disease (AD) is critical for effective therapeutic intervention.
- Amyloid abnormality is an early pathological indicator, with cerebrospinal fluid (CSF) amyloid β1-42 (Aβ42) showing promise but requiring invasive collection.
- Minimally invasive blood-based biomarkers are needed to predict CSF Aβ42 status.
Purpose of the Study:
- To identify a panel of blood-based biomarkers that can accurately predict CSF Aβ42 levels.
- To develop a cost-effective and minimally invasive method for assessing amyloid abnormality in early AD detection.
Main Methods:
- Utilized machine learning to analyze the predictive power of APOE4 genotype and blood markers (EOT3, APOC1, CGA, Aβ42) for CSF Aβ42 status.
- Validated the biomarker signature's performance across multiple machine learning algorithms to ensure generalizability.
Main Results:
- The identified biomarker signature (APOE4, EOT3, APOC1, CGA, Aβ42) demonstrated robust prediction of CSF Aβ42.
- Achieved high classification performance: 0.84 AUC, 0.82 sensitivity, 0.62 specificity, 0.81 positive predictive value (PPV), and 0.64 negative predictive value (NPV).
Conclusions:
- A minimally invasive, cost-effective blood test combining APOE4, EOT3, APOC1, CGA, and Aβ42 can reliably predict CSF Aβ42 status.
- This approach offers a potential first-step diagnostic tool for Alzheimer's disease screening and clinical trial enrichment.
